Has Robert Edward Grant held executive or board positions at public companies?
Executive summary
Publicly available profiles and company pages show Robert Edward (Robert E.) Grant has repeatedly claimed executive and board roles across private and public companies: listings assert he co‑founded Alphaeon and served on its board (linked to Evolus, a NASDAQ company), and that he has held board/director roles at companies including MyoScience, AcuFocus, ReShape Medical and Biolase (a public company), among others [1] [2] [3] [4]. Reporting, corporate bios and aggregate databases differ on titles and timing; sources do not present a single, consolidated official corporate record [5] [1] [2].
1. Public bios and corporate pages list multiple executive and board roles
Biographical pages and corporate sites say Grant founded and led Crown Sterling and Strathspey Crown and that he co‑founded Alphaeon Credit and served on Alphaeon’s board; the Global Entrepreneurship Festival bio also ties him to ALPHAEON Corporation and to assets including Evolus (NASDAQ: EOLS) [1] [6] [4]. Crown Holdings’ own site and The Org profiles list him as Founder/Chairman/Managing Partner of related holding companies and as a board member of ALPHAEON and Zelegent [2] [5].
2. Specific public-company links cited in profiles
Several profiles name companies that are or were publicly traded. GuruFocus and other insider/ownership trackers list Robert E. Grant as VP/COO or insider at Biolase Inc. (BIOLQ) and show an ownership/insider filing trail tied to that ticker [3]. The Global Entrepreneurship Festival description explicitly connects him to ALPHAEON Corporation and notes Evolus (NASDAQ: EOLS) as a subsidiary asset of Strathspey Crown Holdings [4]. MarketScreener and company directories list director positions at Gaia, Inc. and other corporate directorships [7].
3. Discrepancies and variation across sources
Public summaries and fan/aggregate pages differ in titles, dates and emphasis. TheOrg entries show multiple roles (Founder/CEO of CEYEBER, prior CEO of Crown Sterling, founder and board member of AEON Biopharma) while celebrity and profile sites amplify entrepreneurial claims and personal details [5] [1] [8]. MarketScreener, Crown Holdings and The Org emphasize board service at medical‑device firms such as MyoScience, AcuFocus and ReShape Medical, but the timing and formal public‑company filings to corroborate each specific board seat are not uniformly linked in these pages [2] [1] [7].
4. Where sources provide formal public‑company evidence and where they do not
GuruFocus/insider trackers present an SEC‑style insider/ownership summary for Biolase listing Grant as an officer (VP/COO) and reporting owner of an entity tied to BIOLQ, which is the closest thing in the set to a public‑company filing citation [3]. Other claims—such as board service at MyoScience, AcuFocus, ReShape and Gaia—appear on Crown Holdings’ site, The Org and MarketScreener but are not accompanied in these sources by direct SEC filings or press releases in the provided set [2] [1] [7]. Available sources do not mention consolidated, contemporaneous SEC proxy statements or Form 8‑K documents for every named public company.
5. Conflicting perspectives and reputational context
Some outlets provide critical context: RationalWiki describes Crown Sterling as a marginal or “crank” operation in cryptography, challenging technical claims linked to Grant [9]. That critique sits alongside corporate bios and promotional materials praising his inventions and roles, demonstrating competing narratives in the available reporting [2] [9].
6. What is verifiable from this set of sources — and what remains uncertain
Verifiable from the supplied reporting: multiple professional profiles and corporate sites state Grant has held executive and board roles (founder/chairman/CEO roles at Crown Sterling and Strathspey Crown; board/vice‑chair links to ALPHAEON; an insider listing tied to Biolase) [1] [2] [3] [4]. Uncertain or not directly documented in these files: contemporaneous SEC filings or company press releases that would definitively date each public‑company board appointment or resignation; consolidated proof linking every named board seat to a public company filing [1] [2]. Available sources do not mention a single comprehensive corporate record reconciling all claimed public‑company positions.
Bottom line: multiple independent profiles and at least one insider/ownership tracker list Robert E. Grant as having held executive and board roles, including ties to public companies (notably Biolase and associations drawn to Evolus/ALPHAEON), but the supplied reporting includes inconsistencies and lacks a complete set of formal public‑company filings to confirm every named position [3] [1] [2] [4] [9].